OLAPARIB FOR METASTATIC BREAST CANCER AND MUTATIONS IN HOMOLOGOUS RECOMBINATION–RELATED GENES

The authors of this phase II trial evaluated the PARP inhibitor olaparib in the treatment of 54 patients with metastatic breast cancer (76% ER-positive/HER2-negative) and either germline mutations in non-BRCA1/2 homologous recombination–related DNA repair genes (cohort 1) or somatic mutations in BRCA1/2 or other non-BRCA1/2 homologous recombination–related genes (cohort 2). The objective response rate (ORR) […]

OLAPARIB FOR METASTATIC BREAST CANCER AND MUTATIONS IN HOMOLOGOUS RECOMBINATION–RELATED GENES Read More »